PMID- 10235086
OWN - NLM
STAT- MEDLINE
DCOM- 19990520
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 83
IP  - 9
DP  - 1999 May 1
TI  - Effects of aspirin and trapidil on cardiovascular events after acute myocardial 
      infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) 
      Investigators.
PG  - 1308-13
AB  - Aspirin therapy confers conclusive net benefits in the acute phase of evolving 
      myocardial infarction, but no clear evidence of benefit from the long-term use of 
      aspirin after acute myocardial infarction (AMI) has been shown in any single 
      study. This multicenter study, the Japanese Antiplatelets Myocardial Infarction 
      Study, was performed to find out whether aspirin or trapidil would improve 
      clinical outcome compared with no antiplatelets in postinfarction patients. The 
      study was a multicenter, open-label, randomized controlled trial of aspirin 81 
      mg/day, trapidil 300 mg/day, and no antiplatelets in patients with AMI admitted 
      within 1 month from the onset of symptoms. Seven hundred twenty-three patients 
      were enrolled at 70 hospitals in 18 prefectures of Japan; 250 were randomly 
      assigned to treatment with 81 mg aspirin (aspirin group), 243 to that with 
      trapidil (trapidil group), and 230 were not given antiplatelet agents. The mean 
      follow-up period was 475 days. This study demonstrated that long-term use of 
      aspirin at the dose of 81 mg/day reduced the incidence of recurrent AMI compared 
      with the group receiving no antiplatelets after AMI (p = 0.0045) and that 
      trapidil also reduced the occurrence of reinfarction compared with the group 
      receiving no antiplatelets, but the difference was not significant (p = 0.0810). 
      The incidence of cardiovascular events including cardiovascular death, 
      reinfarction, uncontrolled unstable angina requiring admission to hospital, and 
      nonfatal ischemic stroke was reduced in the group receiving 300 mg trapidil daily 
      compared with the group receiving no antiplatelets (p = 0.0039). The use of 
      aspirin 81 mg/day provided almost no benefit over no antiplatelets therapy in the 
      incidence of cardiovascular events. In conclusion, low-dose aspirin (81 mg) 
      effectively prevented recurrent AMI in postinfarction patients after thrombolysis 
      or coronary angioplasty when used over a long term. Furthermore, the long-term 
      use of trapidil resulted in a significant reduction in the incidence of 
      cardiovascular events.
FAU - Yasue, H
AU  - Yasue H
AD  - Department of Cardiovascular Medicine, Kumamoto University School of Medicine, 
      Japan. yasue@gpo.kumamoto-u.ac.jp
FAU - Ogawa, H
AU  - Ogawa H
FAU - Tanaka, H
AU  - Tanaka H
FAU - Miyazaki, S
AU  - Miyazaki S
FAU - Hattori, R
AU  - Hattori R
FAU - Saito, M
AU  - Saito M
FAU - Ishikawa, K
AU  - Ishikawa K
FAU - Masuda, Y
AU  - Masuda Y
FAU - Yamaguchi, T
AU  - Yamaguchi T
FAU - Motomiya, T
AU  - Motomiya T
FAU - Tamura, Y
AU  - Tamura Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Vasodilator Agents)
RN  - EYG5Y6355E (Trapidil)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/prevention & control
MH  - Aspirin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/*prevention & control
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Secondary Prevention
MH  - Time Factors
MH  - Trapidil/*therapeutic use
MH  - Treatment Outcome
MH  - Vasodilator Agents/*therapeutic use
EDAT- 1999/05/11 00:00
MHDA- 1999/05/11 00:01
CRDT- 1999/05/11 00:00
PHST- 1999/05/11 00:00 [pubmed]
PHST- 1999/05/11 00:01 [medline]
PHST- 1999/05/11 00:00 [entrez]
AID - S0002914999000910 [pii]
AID - 10.1016/s0002-9149(99)00091-0 [doi]
PST - ppublish
SO  - Am J Cardiol. 1999 May 1;83(9):1308-13. doi: 10.1016/s0002-9149(99)00091-0.